Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
    Home > Research & Grants > Grants Program > Research Grants > Research Grants Awarded > Basic, Clinical and Translation : 2005-2006

    Research Grants Awarded

    2005-2006 Grant Cycle : Research Grants Awarded

    Basic, Clinical and Translation

    Estrogen Receptor -Tumor Suppressor p53 Interaction: A Basis for Novel Therapeutic Strategies against Breast Cancer
    Gokul Das, PhD
    Roswell Park Alliance Foundation
    Tumor Cell Biology II
    $250,000


    Enhancing Antitumor Cytotoxic T Lymphocyte Function Using HER-2/neu-Specific Monoclonal Antibodies
    Richard Reilly, PhD
    Johns Hopkins University
    Tumor Cell Biology III
    $250,000


    DNA Double-Strand Break (DSB) Repair In Breast Cancer Cells And shRNA Approach To Inhibition Of DSB Repair As A Way To Fight Therapy Resistance
    Vera Gorbunova, PhD
    University of Rochester
    Treatment
    $250,000


    The Roles of p63 and p73 in the Pathogenesis of Mammary Adenocarcinoma
    Elsa Flores, PhD
    U.T.M.D. Anderson Cancer Center
    Tumor Cell Biology V
    $250,000


    Detection and Analysis of Telomere Dysfunction in Breast Tumor Tissue
    David Gilley, PhD
    Indiana University
    Tumor Cell Biology V
    $250,000


    Development of a DNA breast cancer vaccine
    Vasso Apostolopoulos, PhD
    Burnet Institute Incorporating The Austin Research Institute
    Tumor Cell Biology III
    $249,750


    Breast MRI Screening in Women Treated with Mediastinal Irradiation for Hodgkin’s Disease
    Andrea Ng, MD, MPH
    Dana Farber Cancer Institute
    Detection, Diagnosis and Prognosis
    $249,900


    The Effect of Melatonin's Efficacy at Reducing Primary and Metastatic Breast Cancer Risk
    Paula Witt-Enderby, PhD
    Duquesne University
    Psycho-Social and Complementary Treatment
    $250,000


    Bi-specific Endothelin Receptor Antagonists for Breast Cancer Therapy
    Masaki Imai, PhD
    Medical University of South Carolina
    Tumor Cell Biology I
    $248,278


    Adoptive Immunotherapy for HER2 Positive Breast Cancer with Genetically Modified T Cells
    Stephen Gottschalk, MD
    Baylor College of Medicine
    Tumor Cell Biology III
    $250,000


    Mechanisms Underlying the Dual Action of Cellular Retinoic Acid Binding Protein II in Breast Tumor Suppression
    Noa Noy, PhD
    Cornell University
    Tumor Cell Biology II
    $249,722


    Nischarin, a Novel Protein: a Strong Potential Tumor Suppressor and a Prognostic Marker of Breast Cancer
    Suresh Alahari, PhD
    Louisiana State University Health Sciences Center
    Tumor Cell Biology V
    $250,000


    Radiation Targeting of Antivascular Drugs to Tumors
    Mohammad Kiani, PhD
    Temple University of the Commonwealth System of Higher Education
    Tumor Cell Biology I
    $250,000


    Three-dimensional Computerized Detection and Diagnosis of Breast Cancer with Tomosynthesis
    Xuejun Sun, PhD
    H. Lee Moffitt Cancer Center and Research Institute
    Detection, Diagnosis and Prognosis
    $250,000


    Chromosome Instability (CIN) In Breast Cancer Cells
    Katsumi Kitagawa, PhD
    St. Jude Children's Research Hospital
    Tumor Cell Biology V
    $250,000


    The Role of Twist in Mammary Tumor Metastasis
    Douglas Spicer, PhD
    Maine Medical Center
    Tumor Cell Biology I
    $249,756


    Early detection of high-risk patients with breast DCIS
    S. Ashraf Imam, MS, PhD
    Huntington Medical Research Institutes
    Detection, Diagnosis and Prognosis
    $250,000


    Paced breathing for hot flashes in breast cancer survivors: a randomized Phase II study
    Amit Sood, MD
    Mayo Clinic Rochester d/b/a Mayo Clinic College of Medicine
    Psycho-Social and Complementary Treatment
    $250,000


    The tumor stroma as a regulator of resistance to endocrine therapy.
    Marina Simian, PhD
    Instituto de Oncologia Angel H. Roffo
    Tumor Cell Biology II
    $249,999


    BP1 Expression, Apoptosis, and Breast Cancer Aggressiveness in African American Women
    Patricia Berg, PhD
    The George Washington University
    Tumor Cell Biology V
    $250,000


    Development of biological models to differentiate aggressive from indolent DCIS
    Rachel Ellsworth, PhD
    Windber Research Institute
    Detection, Diagnosis and Prognosis
    $249,998


    Molecular Targeting Of DNA Repair: Determining The Functional Status Of The FA/BRCA Pathway In Non-Familial Breast Cancers
    Lisa Kachnic, MD
    Massachusetts General Hospital
    Tumor Cell Biology V
    $249,974


    Synergy Between ErbB2 And The Breast Tumor Kinase Brk
    W. Todd Miller, PhD
    The Research Foundation
    Tumor Cell Biology V
    $249,906


    Prevention of Early Pre-malignant Breast Lesions by an Aurora Kinase Inhibitor during Estrogen-induced ACI Rat Breast Oncogenesis
    Jonathan Li, PhD
    University of Kansas Medical Center
    Treatment
    $248,413


    The Use of Zoledronate to Impact Organ Metastasis in Breast Cancer Patients
    Barbara Fingleton, PhD
    Vanderbilt University Medical Center
    Tumor Cell Biology IV
    $250,000


    Molecular Mechanisms Responsible for the Neighbor Effect, the Mesenchymal Transition Induced in TGF-beta non-responsive Breast Cancer Cells by Adjacent Epithelial Cells
    Michael Hoffmann, PhD
    Board of Regents of the University of Wisconsin System
    Tumor Cell Biology II
    $248,620


    Targeting STAT1 in the Treatment of Breast Cancer
    David Frank, MD, PhD
    Dana-Farber Cancer Institute
    Treatment
    $250,000


    Genomic study of familial DCIS and invasive breast cancer to discover susceptibility genes
    Wendy Rubinstein, MD, PhD
    Evanston Northwestern Healthcare Research Institute
    RISK and Prevention, Epidemiology
    $250,000


    Breast Cancer and the Plasminogen Activator Inhibitor-1 Cycle
    Frank Church, PhD
    University of North Carolina at Chapel Hill
    RISK and Prevention, Epidemiology
    $250,000


    Individualized Risk Information System (IRIS) for BRCA Carriers
    Jeffrey N. Weitzel, MD
    Beckman Research Institute of the City of Hope
    RISK and Prevention, Epidemiology
    $250,000


    Caffeic Acid Phenethyl Ester (CAPE, Product of Propolis) as Potential Preventive and/or Therapeutic Agent for Breast Cancer
    Krystyna Frenkel, PhD
    New York University School of Medicine
    RISK and Prevention, Epidemiology
    $249,764


    Phenotypic Differences in Sub-types of DCIS: Aggressiveness and Race
    William Grizzle, MD, PhD
    The Board of Trustees of the Universtiy of Alabama for the University of Alabama at Birmingham
    Detection, Diagnosis and Prognosis
    $250,000


    ATF-3: A Potential Target Gene for Breast Cancer Cell Growth and Metastasis
    Nagarajan Selvamurugan, PhD
    University of Medicine & Dentistry of New Jersey
    Tumor Cell Biology II
    $250,000


    Penetratin-Based Vaccines for the Treatment of Breast Cancer
    Geoffrey Pietersz, PhD
    Burnet Institute at Austin, Kronheimer Building
    Tumor Cell Biology III
    $242,040


    Targeted Gene Therapy for Breast Cancer Growth and Metastasis
    Selvarangan Ponnazhagan, PhD
    The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
    Treatment
    $250,000


    A Novel Herbal Medicine for Treatment of Breast Cancer
    Damodaran Chendil, PhD
    Univeristy of Kentucky Research Foundation
    Psycho-Social and Complementary Treatment
    $250,000


    The Tumor Suppressing Effect of Pregnancy: Can the Mammary Stroma do the Job?
    Maricel Maffini, PhD
    Tufts University
    Tumor Cell Biology IV
    $250,000


    Molecular Network Profiling of DCIS for Patient Stratification and Individualized Therapy
    Kirsten Edmiston, MD
    Inova Fairfax Hospital Cancer Center
    Detection, Diagnosis and Prognosis
    $250,000


    Modeling Breast Cancer Initiation Through Genetic Manipulation of Mammary Stem Cells
    James DiRenzo, PhD
    Trustees of Dartmouth College
    Tumor Cell Biology V
    $250,000


    Telomere Dysfunction and Breast Cancer Risk
    Yun-Ling Zheng, MD, PhD, MPH
    Georgetown University
    RISK and Prevention, Epidemiology
    $249,923


    Sonography Compared with MRI in Pre-operative Evaluation of Patients with Breast Cancer to Determine Extent of Breast Disease
    Linda Hovanessian-Larsen, MD
    University of Southern California
    Detection, Diagnosis and Prognosis
    $245,117


    Role Of CD1D1 In Breast Cancer Bone Metastasis
    Ming Zhang, PhD
    Baylor College of Medicine
    Tumor Cell Biology IV
    $250,000


    Endoplasmic Reticulum Stress Induced Apoptosis of Capillary Endothelia: A New Target for Treating Breast Cancer
    Dipak Banerjee, PhD
    University of Puerto Rico - Medical Sciences Campus
    Tumor Cell Biology I
    $250,000


    Combination immunotherapy of established breast cancer
    Mark Smyth, PhD
    Universty of Melbourne
    Tumor Cell Biology III
    $249,960


    Estrogen Receptor Beta in Relation to Breast Cancer Proliferation
    Guojun Cheng, MD, PhD
    Dept. of Biosciences and Nutrition, Karolinska Institutet
    Tumor Cell Biology II
    $249,300


    Prevention of chromosomal instability in breast cancer by indigo-derived CDK inhibitors
    Stefan Duensing, MD
    University of Pittsburgh
    RISK and Prevention, Epidemiology
    $249,814


    Mechanisms of breast cancer-preventive effects of organosulfur compounds
    Yong Lee, PhD
    University of Pittsburgh
    RISK and Prevention, Epidemiology
    $250,000


    Investigation of the Diagnostic Value of Diffusion Tensor MRI of the Breast
    Savannah Partridge, PhD
    University of Washington
    Detection, Diagnosis and Prognosis
    $243,619


    Signaling Cross-Talk Converging On Survivin During Anti-Tumor Drug Action: A Potential New Concept For Breast Cancer Treatment
    Fengzhi Li, PhD
    Roswell Park Alliance Foundation
    Treatment
    $250,000


    Breast Magnetic Resonance Assessment of Tumor Viability After Radiofrequency Ablation
    Todd Tuttle, MD
    The Regents of the University of Minnesota
    Detection, Diagnosis and Prognosis
    $250,000


    Novel Array-Based Identification of Genes Causing Chemotherapy Resistance by Breast Cancer
    Dan Mercola, MD, PhD
    The Regents of the University of California
    Tumor Cell Biology IV
    $250,000


    Polyamine Analogues As Novel Anti-Estrogen Receptor Alpha Agents
    Nancy Davidson, MD
    Johns Hopkins University, School of Medicine
    Tumor Cell Biology II
    $250,000


    Lipid-induced breast cancer metastasis
    Erhard Bieberich, PhD
    Medical College of Georgia
    Tumor Cell Biology I
    $250,000


    Synthesis Of Signal Transduction Inhibitor-Steroidal Antiestrogen Hybrids Using "Click Chemistry" And Their Evaluation As Breast Cancer Therapeutic Agents
    Robert Hanson, PhD
    Northeaster University
    Treatment
    $236,250


    Targeting Breast Cancer at the Level of Translation Control
    Matthias Gromeier, MD
    Duke University
    Tumor Cell Biology IV
    $240,000


    Sesquiterpene Lactones: Aspirins for Breast Cancer
    Michael Van Dyke, PhD
    The University of Texas M.D. Anderson Cancer Center
    Tumor Cell Biology V
    $249,000


    Developing Anti-Breast Cancer Therapies Based on G3BP
    Derek Kennedy, PhD
    Griffith University
    Tumor Cell Biology III
    $247,478


    Estrogen and Progestin Regulation of Thrombospondin-1 in Breast Cancer Cells
    Salman Hyder, PhD
    The Curators of the University of Missouri
    Tumor Cell Biology I
    $250,000


    The Role Of Dietary Antioxidants And Expression Of Nm23-H1 In Breast Cancer Skeletal Metastasis
    Craig Albright, PhD

    Tumor Cell Biology IV
    $250,000


    Annexin/lipocortin I as a unique target of mechanism-based chemoprevention of breast cancer: computer biology and in vitro new gene mutation assays.
    Fusao Hirata, MD, PhD
    Wayne State University
    RISK and Prevention, Epidemiology
    $250,000


    P-TEFB, A NOVEL THERAPEUTIC TARGET FOR HUMAN BREAST CANCER
    Qiang Zhou, PhD
    The Regents of the University of California at Berkeley
    Tumor Cell Biology II
    $250,000


    Regulation of SXR Activation by Rexinoids - Role in Drug Resistance
    Wilson Miller, MD, PhD
    Lady Davis Institute for Medical Research, McGill University
    Tumor Cell Biology II
    $242,765


    Modulation Of Erbb2 Tumor Metabolism By Akt
    Steven Anderson, PhD
    Health Sciences Center, University of Colorado System
    Tumor Cell Biology IV
    $250,000


    Characterization of the Cytotoxic CD8+ T Cell Immune Response to Mammaglobin-A
    Andres Jaramillo, PhD, HCLD(ABB)
    Rush University Medical Center
    Tumor Cell Biology III
    $249,000


    Improving Mammography Performance with Tomosynthesis
    David Gur, ScD
    University of Pittsburgh, Office of Research
    Detection, Diagnosis and Prognosis
    $249,789


    A Phase II Study Of Tetrathiomolybdate, An Anti-Angiogenic Agent, In Women With Breast Cancer At High Risk Of Relapse
    Linda Vahdat, MD
    Joan & Sanfor I. Weill Medical College of Cornell University
    Treatment
    $250,000


    Whole-body MRI for Detecting Breast Cancer Metastases
    Jingfei Ma, PhD
    UT M.D. Anderson Cancer Center
    Detection, Diagnosis and Prognosis
    $225,900


    Uric Acid Crystals as a Novel Adjuvant for HER-2/neu-Based Immunotherapy in a Somatic Mammary Carcinoma Model
    Xiulong Xu, PhD
    Rush University Medical Center
    Tumor Cell Biology III
    $247,008


    Inhibition of Breast Cancer Tumor Progression by Class-3 Semaphorins
    Gera Neufeld, PhD
    Technion Research & Development Foundation, Ltd.
    Tumor Cell Biology I
    $249,900


    Regulation of novel cytoskeletal protein complexes involved in breast cancer initiation and progression
    Anton Wellstein, MD, PhD
    Georgetown University, Lombardi Comprehensive Cancer Center
    Tumor Cell Biology I
    $250,000


    Role of IFIX in breast cancer metastasis
    Mien-Chie Hung, PhD
    The University of Texas M.D. Anderson Cancer Center
    Tumor Cell Biology I
    $250,000


    Dietary Glutamine And Protection Against Doxorubicin And Cyclophosphamide Toxicity
    Valentina Todorova, PhD
    The Board of Trustees of the University of Arkansas Acting for and on behalf of the University of Arkansas for Medical Services
    Treatment
    $249,356


    Evaluating Akt Tyrosine Phosphorylation as a Novel Marker for Therapeutic Resistance and Breast Cancer Prognosis
    Thomas Franke, MD, PhD
    Columbia University Medical Center
    Tumor Cell Biology V
    $250,000


    Multiplexed Biomarkers for Early Detection and Remission Monitoring of Breast Cancer
    Anna Lokshin, PhD
    University of Pittsburgh
    Detection, Diagnosis and Prognosis
    $249,837


    Deuterium Labeling in DCIS: A Novel In Vivo Measure of Cell Proliferation
    E. Shelley Hwang, MD
    University of California, San Francisco
    Detection, Diagnosis and Prognosis
    $248,490


    Role of Protein Kinase C delta in Mammary Gland Apoptosis and Tumorigenesis
    Mary Reyland, PhD
    University of Colorado at Denver and Health Sciences Center
    Tumor Cell Biology V
    $250,000


    Human Papillomavirus Infection As A Potential Cause of Breast Cancer
    Michelle Ozbun, PhD
    The Regents of the University of New Mexico
    Tumor Cell Biology V
    $250,000


    Distinct function and role of androgen receptor cofactor ARA70alpha and ARA70beta isoforms in breast cancer growth and metastasis
    Peng Lee, MD, PhD
    New York University School of Medicine
    Tumor Cell Biology II
    $250,000


    ER-alpha36 and development of ER-negative breast cancer
    Zhaoyi Wang, PhD
    Creighton University
    Tumor Cell Biology I
    $250,000


    The Functions of Brca1 and Brca2 in Protecting Stalled DNA Replication Forks
    Lee Zou, PhD
    The General Hospital Corporation
    Tumor Cell Biology V
    $250,000


    Elucidating the Cause for the Insrease in Telomerase in Human Breast Cancer
    Trygve Tollefsbol, PhD, DO
    The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham
    Tumor Cell Biology V
    $250,000


    The 3D telomeric signature(s) of DCIS
    Sabine Mai, PhD
    The University of Manitoba
    Detection, Diagnosis and Prognosis
    $249,805


    Regulation of Breast Cancer by Progesterone Metabolites
    John Wiebe, PhD
    University of Western Ontario
    Tumor Cell Biology IV
    $250,000


    Mammary Cancer Stem Cells
    Anne Peaston, PhD
    The Jackson Laboratory
    Tumor Cell Biology V
    $250,000


    Ductal Carcinoma In Situ and BRCA1/2: Outcomes and Risk Prediction
    Elizabeth Claus, PhD, MD
    Yale University
    RISK and Prevention, Epidemiology
    $249,823


    Use of BOEC for Cancer Gene Therapy
    Arkadiusz Dudek, MD, PhD
    Regents of the University of Minnesota
    Treatment
    $250,000


    Real-Time Imaging of Human Breast Tissue by Reflectance Confocal Microscopy
    Minetta Liu, MD
    Georgetown University
    Detection, Diagnosis and Prognosis
    $250,000


    In Vitro and In Vivo Models for Chemoresistance
    Nira Ben-Jonathan, Ph.D
    University of Cincinnati
    Tumor Cell Biology IV
    $250,000


    Predicting Outcome in Node-Negative Breast Cancer by Integrated Genomics and Proteomics
    Yuval Kluger, PhD
    New York University School of Medicine
    Detection, Diagnosis and Prognosis
    $250,000


    Restoring ER Expression and Anti-Estrogen Response to ER-Negative Breast Cancers
    Dorraya El-Ashry, PhD
    The Regents of the University of Michigan
    Tumor Cell Biology II
    $250,000


    Targeting Fatty Acid Synthase (FAS)-Dependent Endogenous Fatty Acid Metabolism To Prevent Breast Cancer: FAS As A Metabolic Oncogene In Situ Ductal Carcinoma Of The Breast
    Javier Menendez, PhD
    Fundacio Privada D'Investigacio Biomedica de Giorna
    Tumor Cell Biology V
    $249,991


    BC200 RNA: a novel molecular marker for DCIS and invasive breast cancer
    Henri Tiedge, PhD
    The Research Foundation of SUNY on behalf of Health Science Center at Brooklyn, SUNY
    Detection, Diagnosis and Prognosis
    $250,000


    Human prolactin as a chemopreventive agent for breast cancer
    Wen Chen, PhD
    Greenville Hopital System
    RISK and Prevention, Epidemiology
    $250,000


    Skeletal Metastasis and the Unique Role of Breast Cancer Stem Cells
    Peter Hauschka, PhD
    Children's Hospital Boston
    Tumor Cell Biology I
    $250,000


    Combination Therapy Based on Novel Vitamin D Actions to Inhibit Breast Cancer Cell Growth
    David Feldman, MD
    Stanford University
    Treatment
    $250,000


    Molecular synergy and novel targets of anti-breast cancer phytochemicals
    Joseph Wu, PhD
    New York Medical College
    RISK and Prevention, Epidemiology
    $250,000


    Regulation of ER transcriptional potential by the chromatin architectural factor HMGB1
    Wei Xu, PhD
    Board of Regents of the University of Wisconsin System
    Tumor Cell Biology II
    $249,695


    Role of Mitotic Checkpoint in the Sensitivity of Breast Cancer to Paclitaxel
    Naoto Ueno, MD,PhD
    The University of Texas M.D. Anderson Cancer Center
    Tumor Cell Biology IV
    $250,000


    Breastfeeding History And Undifferentiated Breast Cancer
    William Fraser Symmans, MD
    The University of Texas, M.D. Anderson Cancer Center
    RISK and Prevention, Epidemiology
    $249,209


    A Novel Three-Dimensional Model of Basal-like Breast Cancer
    Vincent Cryns, MD
    Northwestern University
    Tumor Cell Biology V
    $250,000


    Isolation of metastasis-inhibiting monoclonal antibodies
    Steve Goodison, PhD
    University of Florida
    Detection, Diagnosis and Prognosis
    $249,559


    Do Mast Cells Prevent Carcinogenesis?
    Ana Soto, MD
    Tufts University
    Tumor Cell Biology III
    $250,000


    Use of a Panel of Mitotic Kinase Antibodies to Predict Pre-malignancy Outcomes in Human Breast Cancer
    Sara Li, PhD
    University of Kansas Medical Center
    Detection, Diagnosis and Prognosis
    $249,208


    Design of Targeted Bacteria to Overcome Multidrug Resistance
    Neil Forbes, PhD
    The University of Massachusetts, Office of Grant and Contract Admin.
    Treatment
    $249,830


    Discovery and Functional Analysis of Fusion Transcripts In Breast Cancer
    Colin Collins, PhD
    University of California, San Francisco
    Tumor Cell Biology V
    $250,000


    Minor Recombination Pathways, Cellular Survival, And Tumorigenesis In The Absence Of BRCA2
    Maria Jasin, PhD
    Memorial Sloan-Kettering Cancer Center
    Tumor Cell Biology V
    $250,000


    The Role of the Rho Exchange Factor NET1 in Breast Cancer
    Jeffrey Frost, PhD
    The University of Texas Health Science Center at Houston
    Tumor Cell Biology V
    $250,000


    Mapping The Mammary Epithelial Cell Transformation In BRCA1 Carriers
    Gerburg Wulf, MD PhD
    Beth Israel Deaconess Medical Center
    Tumor Cell Biology V
    $249,945


    Identification Of Low Molecular Weight Serum Proteins/Peptides For The Diagnosis Of Breast Cancer Disease
    Tapan Maity, PhD
    Windber Research Institute
    Detection, Diagnosis and Prognosis
    $247,870


    A New In Vitro Model of Breast Cancer Metastasis to Bone
    Andrea Mastro, PhD
    The Pennsylvania State University
    Tumor Cell Biology I
    $250,000


    Determinants of Weight Gain in Women with Early Stage Breast Cancer
    Chi-Chen Hong, PhD
    Roswell Park Alliance Foundation
    RISK and Prevention, Epidemiology
    $250,000


    The role of G12 proteins in breast cancer invasion and metastasis
    Timothy Fields, MD, PhD
    Duke University
    Tumor Cell Biology I
    $250,000


    Three-Dimensional Analysis of Shoulder Motion Limitation Following Treatment for Breast Cancer
    John Borstad, PhD
    The Ohio State University Research Foundation
    Treatment
    $168,739


    Mechanisms of Cognitive Dysfunction in Breast Cancer Survivors
    Ian Tannock, MD, PhD
    University Health Network
    Psycho-Social and Complementary Treatment
    $249,680


    Evaluating the Role of GKLF/KLF4 in Mammary Gland Development and Carcinogenesis
    Ruth Keri, PhD
    Case Western Reserve University
    Tumor Cell Biology V
    $250,000


    Inhibition Of Constitutive Stat3 Pathway In Breast Cancer Cells By A Novel Low-Molecular-Weight Compound
    Jiayuh Lin, PhD
    Children's Research Institute
    Treatment
    $250,000


    Role of GluR6 in cell senescence and in the development of breast cancer
    Raghbir Athwal, PhD
    Temple University
    Tumor Cell Biology I
    $250,000


    CXCR:4 Wnt Axis in Chemoresistance of Breast Cancer Stem Cells
    Harikrishna Nakshatri, BVSc, PhD
    Indiana University
    Tumor Cell Biology I
    $250,000


    Androgen receptor status as a determinant of breast cancer risk and disease progression.
    Wayne Tilley, PhD
    The University of Adelaide
    Tumor Cell Biology II
    $247,500


    A Novel Target for Preventing Both Immune Tolerance and Tumor Angiogenesis to Improve Immune Enhancing Therapy for Advanced Breast Cancer
    Ping-Ying Pan, PhD
    Mount Sinai School of Medicine of NYU
    Tumor Cell Biology III
    $249,999


    Mechanisms of aberrant growth signaling in a rat model of early-onset breast cancer
    Susan Ozanne, BSc (Hons), Ph.D.
    University of Cambridge
    RISK and Prevention, Epidemiology
    $248,745


    Understanding Adjuvant Therapy and Clinical Trials: An Evaluation of an Online Synthetic Interview for Breast Cancer Patients
    Valerie Monaco, PhD, MHCI
    University of Pittsburgh
    Psycho-Social and Complementary Treatment
    $250,000


    Identification of biomarker for activator form of estrogen-related receptor alpha in breast cancer
    Janet Mertz, PhD
    Board of Regents of the University of Wisconsin System
    Tumor Cell Biology II
    $249,582


    The SDF1-CXCR4 Axis In Breast Cancer Progression And Endocrine Resistance
    Matthew Burow, PhD
    Tulane University Health Sciences Center
    Tumor Cell Biology II
    $250,000


    Targeting the Neovasculature for Immunotherapy and Photodynamic Therapy of Breast Cancer
    Zhiwei Hu, MD, PhD
    Yale University
    Treatment
    $250,000


    Identifying New Biomarkers for Breast Cancer using Antibody Microarray Staining
    Wayne Zhou, PhD
    Baton Rouge, LSU
    Detection, Diagnosis and Prognosis
    $250,000


    Shear Strain Imaging for Breast Cancer Diagnosis
    Tomy Varghese, PhD
    The Board of Regents of the University of Wisconsin System
    Detection, Diagnosis and Prognosis
    $249,990


    Validation of SHIP2 as a Novel Molecular Target in Obesity-Linked Cancer’
    Nagendra Prasad, DVM, PhD
    Purdue University
    Tumor Cell Biology II
    $250,000


    Serum Glycan Analysis in Breast Cancer
    Helen Chew, MD
    The regents of the University of California
    Detection, Diagnosis and Prognosis
    $250,000


    A pilot study of synthetic thyrotropin-releasing hormone (TRH) administration for the treatment of radiation therapy induced fatigue in breast cancer patients
    Andrew Winokur, MD PhD
    University of Connecticut Health Center
    Psycho-Social and Complementary Treatment
    $44,250


    Methylated CpG islands as biomarkers for familial breast cancer
    Georgia Chenevix-Trench, PhD
    Queensland Institute of Medical Research
    Detection, Diagnosis and Prognosis
    $249,928


    Role of CRIF1 in NRF2 signaling pathway
    Insoo Bae, PhD
    Georgetown University
    RISK and Prevention, Epidemiology
    $250,000


    Immunologic Gene Expression in Sentinel Lymph Nodes
    Steve Shivers, PhD
    Lakeland Regional Cancer Center
    Detection, Diagnosis and Prognosis
    $250,000


    Time-Dependent Patterns of Tumor Recurrence and Other Events After Early Stage Breast Cancer
    James Dignam, PhD
    University of Chicago
    Detection, Diagnosis and Prognosis
    $249,078


    Role of MT1-MMP in protection of breast tumor cells against host immune attack
    Alex Strongin, PhD
    Burnham Institute for Medical Research
    Tumor Cell Biology I
    $250,000


    Development of 3D Microfluidic Gradient Model for Metastasis
    Noo Li Jeon, PhD
    The Regents of the University of California
    Tumor Cell Biology I
    $249,927


    Rational Design of Combinational Targeted Therapeutics in Breast Cancer: Towards Improving Patient Outcomes
    Yiling Lu, MD
    The University of Texas M.D. Anderson Cancer Center
    Treatment
    $250,000


    Breast Positioning And Topology Monitoring System Development For Image-Guided Radiation Therapy
    Jason Sohn, PhD
    Case Western Reserve University
    Treatment
    $250,000


    Glycoproteomic Identification of Prognostic Serum Biomarkers
    Richard Drake, PhD
    Eastern Virginia Medical School
    Detection, Diagnosis and Prognosis
    $250,000


    Defining The Clinical And Functional Role Of An Extracellular Matrix Gene Cluster In Therapy Failure
    Petronella Berns, PhD
    Erasmus University Medical Center Rotterdam
    Treatment
    $250,000


    Feasibility study of a high-resolution breast coil for PET-CT scanners
    Yuan-Chuan Tai, PhD
    Washington University
    Detection, Diagnosis and Prognosis
    $249,349


    Prognostic Significance of Soluble EGFR Expression in Breast Cancer
    Jill Reiter, PhD
    Yale University
    Detection, Diagnosis and Prognosis
    $250,000


    Identifying Therapeutic Targets by Expression Profiling of DNA Repair in Breast Cancer
    Alexander Dobrovic, PhD
    The University of Melbourne
    Detection, Diagnosis and Prognosis
    $249,200


    Identifying New Tumor Suppressor Genes Involved In Human Breast Cancer
    Mieke Schutte, PhD
    Erasmus MC
    Tumor Cell Biology V
    $248,800


    Tracking Response to Tamoxifen Prevention
    Victoria L. Seewaldt, MD
    Duke University School of Medicine
    Treatment
    $250,000


    Understanding and Improving the Effectiveness of Trastuzumab-Based Therapy for Breast Cancer
    Randall King, MD, PhD
    President and Fellows of Harvard College on behalf of Harvard Medical School
    Tumor Cell Biology IV
    $250,000


    translational control of metastases
    Arrigo De Benedetti, PhD
    LSU Health Science Center - Shreveport
    Tumor Cell Biology I
    $247,020


    Role Of TBX3 In Breast Cancer
    Taosheng Huang, MD, PhD
    The Regents of the University of California
    Tumor Cell Biology V
    $247,225


    Volumetric Estimation of Breast Percent Density from Tomosynthesis Images
    Predrag Bakic, PhD

    Detection, Diagnosis and Prognosis
    $250,000


    Comparison of the IGF and Breast Density Association by Race
    Celia Byrne, PhD
    Georgetown University
    RISK and Prevention, Epidemiology
    $250,000


    Targeting JNK to Block Breast Cancer Proliferation and Metastasis
    Xiaojiang Cui, PhD
    Baylor College of Medicine
    Tumor Cell Biology I
    $249,947


    MMP1-Protease Activated Receptor-1 Signaling in the Tumor-Stromal Microenvironment
    Athan Kuliopulos, MD, PhD
    New England Medical Center Hospitals, Inc.
    Tumor Cell Biology I
    $250,000


    Single Molecule Studies of Homologous Recombination in Human Cells
    Piero Bianco, PhD
    The Research Foundation of SUNY on behalf of University at Buffalo
    Tumor Cell Biology V
    $249,583


    Control of mammary epithelial hyperplasia and malignant progression by p21-activated kinase 1 (PAK1)
    Ray Mattingly, PhD
    Wayne State University
    Tumor Cell Biology II
    $250,000


    "Genetic Modifiers of BRCA Penetrance"
    Kenneth Offit, MD, MPH
    Memorial Sloan-Kettering Cancer Center
    RISK and Prevention, Epidemiology
    $249,919


    Multiple Flavonoids in the Treatment of Multidrug Resistance
    Marilyn Morris, PhD
    Buffalo, State University of New York System
    Treatment
    $250,000



    * Pending executed agreement